Nephroprotective role of resveratrol and ursolic acid in aristolochic acid intoxicated zebrafish by Ding YJ, Sun CY, Wen CC, Chen YH & [[corresponding]]Chen YH






Nephroprotective Role of Resveratrol and Ursolic Acid in 
Aristolochic Acid Intoxicated Zebrafish 
Yu-Ju Ding 1, Chiao-Yin Sun 2, Chi-Chung Wen 3 and Yau-Hung Chen 1,* 
1 Department of Chemistry, Tamkang University, No. 151 Ying-chuan Road, Tamsui,  
New Taipei City 25137, Taiwan; E-Mail: dingfion@gmail.com 
2 Department of Nephrology, Chang Gung Memorial Hospital, Keelung 20491, Taiwan;  
E-Mail: fish3970@gmail.com 
3 Department of Mathematics, Tamkang University, Tamsui, New Taipei City 25137, Taiwan;  
E-Mail: ccwen@mail.tku.edu.tw 
* Author to whom correspondence should be addressed; E-Mail: yauhung@mail.tku.edu.tw;  
Tel.: +886-2-2621-5656 (ext. 3009); Fax: +886-2-2620-9924. 
Academic Editor: John P. Berry 
Received: 6 September 2014 / Accepted: 5 January 2015 / Published: 13 January 2015 
 
Abstract: The nephrotoxicity of aristolochic acid (AA) is well known, but information 
regarding the attenuation of AA-induced toxicity is limited. The aim of the present study 
was to study the nephroprotective effects of resveratrol (Resv) and ursolic acid (UA) in a 
zebrafish model. We used two transgenic lines, Tg(wt1b:EGFP) and Tg(gata1:DsRed),  
to evaluate the nephroprotective effects of Resv and UA by recording subtle changes in the 
kidney and red blood cell circulation. Our results demonstrated that both Resv and UA 
treatment can attenuate AA-induced kidney malformations and improve blood circulation. 
Glomerular filtration rate assays revealed that both Resv and UA treatment can restore renal 
function (100% for Mock; 56.1% ± 17.3% for AA-treated; 80.2% ± 11.3% for Resv+AA; 
and 83.1% ± 8.1% for UA+AA, n = 15). Furthermore, real-time RT-PCR experiments 
showed that pre-treatment with either Resv or UA suppresses expression of pro-inflammatory 
genes. In conclusion, our findings reveal that AA-induced nephrotoxicities can be attenuated 
by pre-treatment with either Resv or UA. Therefore, we believe that zebrafish represent an 
efficient model for screening AA-protective natural compounds. 
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Serious damage to the kidney, a very delicate organ, increases the rate of uremic bleeding. This leads 
to renal failure, a life-threatening disease. Most of the patients undergo dialysis as a long-term treatment 
because no specific medication has been developed [1]. Therefore, investigation of the causes of renal 
damage and development of new methods for preventing renal damage are needed. 
There are many risk factors that have been demonstrated to be highly associated with renal failure. 
Exposure to xenobiotics, such as antibiotics, heavy metals, aristolochic acid-containing traditional 
Chinese herbs and other natural toxins, is considered to be the main cause of renal damage [2,3]. 
Accompanied by xenobiotic-induced inflammation, such exposures often cause serious kidney injuries. 
For example, mice treated with cisplatin had an accumulation of leukocytes and upregulation of  
pro-inflammatory molecules, which consequently caused tubular damage and acute kidney injury [4]. 
These observations indicate that exposure to a toxin, combined with subsequent inflammation, increase 
the risk of renal damage. 
Aristolochic acid (AA) is found primarily in herbal extracts and can induce clinical  
nephropathy [5,6]. Epidemiological studies have shown that aristolochic acid nephropathy (AAN) is 
associated with a high long-term risk for renal failure and urothelial cancer [7,8]. In Taiwan, 
approximately one-third of the population has been prescribed herbal remedies containing Aristolochia, 
and the recorded incidence of urinary tract cancers is the highest in the world [9]. In several AAN 
patients, foci of inflammatory cells infiltrating into the corticomedullary junctions were also found [10]. 
In rats, accumulation of monocytes/macrophages and T lymphocytes and AA-induced inflammation 
cause renal injury [11]. In zebrafish, our previous study showed that AA-exposure caused acute 
inflammation that led to malformation of embryonic zebrafish heart and kidney [12]. 
Because drug-induced inflammation may be the major cause of renal failure, anti-inflammatory 
agents should have the potential to attenuate renal failure. Resveratrol (Resv) and ursolic acid (UA) are 
rich in grape and apple peels, both of which are well-known natural anti-inflammatory agents [13,14].  
It has been shown that UA can be used to prevent liver damage through restraining the activation of toxic 
ingredients, and boosting immunity [15–17]. Moreover, Resv is found to be capable of simultaneously 
restraining the production of reactive oxygen species (ROS) within and without cells. As a result, these 
agents can prevent diseases caused by oxidative stress. Castro et al. [18] reported that Resv can reduce 
the expression of MPO and restrain the production of inflammation. Because of their anti-inflammatory 
activity, Resv and UA are often used to prevent and treat immune-mediated diseases [19,20].  
These observations suggest that Resv and UA may have the potential to attenuate or to prevent  
inflammation-induced renal malformations. 
Zebrafish represent a very effective animal model for toxicological studies [21–26]. In the present study, 
we attempted to investigate the nephroprotective roles of Resv and UA in a zebrafish model.  
We utilized the transgenic lines Tg(wt1b:EGFP) and Tg(gata1:DsRed) to study the resulting subtle 
changes in the kidney and the red blood cells, respectively. We also generated a series of time- and  
dose-dependent AA exposure experiments. We hope to establish a whole-organism drug screening 
platform to select more useful natural compounds for the prevention of nephropathy. 
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2. Results and Discussion 
2.1. Resv/UA Has No Evident Effects for Enhancing Survival Rates of AA-Intoxicated Zebrafish Embryos 
To study the protective effects of Resv/UA on AA-induced renal malformations, we first treated 
zebrafish embryos with AA (3 ppm) at 24–31 hpf to cause kidney malformation and then treated with 
the desired concentrations (0, 1, 10 and 20 ppm) of either Resv or UA and calculated their survival rates 
(Figure 1). The results revealed that 77.8% ± 9.6% to 86.7% ± 9.6% (mean ± standard error;  
n = 30 (number of embryos; N = 5, repeated for 5 times) of the AA-exposed embryos were alive at  
72 hpf, while 83.3% ± 4.7% to 90.0% ± 9.4% (n = 30, N = 5; UA+AA) and 86.7% ± 14.5% to  
90.0% ± 5.8% (n = 30, N = 5; Resv+AA) of embryos were alive, indicating no evident differences in 
survival rates between AA treatment and prevention groups (UA+AA and Resv+AA). 
 
Figure 1. (A) Administration methods for the four processing modes utilized in this study. 
Mock: Embryos were incubated in egg water; aristolochic acid (AA): Embryos were exposed 
to 3 ppm AA at 24–31 hpf; and resveratrol (Resv)+AA or ursolic acid (UA)+AA groups: 
Embryos were treated with Resv or UA at 12–24 hpf (1, 10 and 20 ppm) and then exposed 
to AA at 24–31 hpf; (B) Survival rates of embryos in the prevention method. Embryos were 
incubated in water (mock), exposed to 3 ppm AA only (AA control), or treated with 1, 10 
and 20 ppm Resv or UA following exposure to 3 ppm AA. The X- and Y-axes represent the 
developmental stages and the survival rates, respectively. 
2.2. Resv and UA Can Attenuate Aristolochic Acid-Induced Kidney Malformation 
The transgenic Tg(wt1b:EGFP) zebrafish, in which the glomerulus, pronephric tube, pronephric duct 
and exocrine pancreas can be easily observed by green fluorescence, is a useful tool for studying 
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nephrotoxicities, especially for high throughput pipeline analysis [12,25,26]. The present study 
employed the transgenic line Tg(wt1b:EGFP) as a model to evaluate the protection effects of Resv  
and UA. Our results showed that AA-exposed zebrafish displayed more malformed kidney phenotypes 
than those in the mock control group at 48 hpf. Those malformed kidney phenotypes include (1) curved 
and dilated pronephric tubules and (2) a swollen and unfused glomerulus (Figure 2A vs. 2B). 
Interestingly, those AA-induced kidney malformations can be attenuated by pre-treatment with either 
Resv or UA (Figure 2C,D). 
To further evaluate the protective effects of Resv and UA using statistical analyses, we first applied 
the ANOVA method to examine the dosage effect (0, 1, 10 and 20 ppm) on the malformation rate for 
the two drugs (Resv and UA) separately. The tests give very small p-values (<0.0001) for both “Resv” 
and “UA” treatments, indicating a highly significant difference between dosage groups for each drug 
treatment. The Tukey-Kramer HSD test was then used for pairwise comparison of the mean 
malformation rates of dosage groups for the drugs “Resv” and “UA”. For “Resv”, the test reports that 
the mean malformation rates (standard error, sample size) for four dose groups (AA only, AA+Resv  
1 ppm, AA+Resv 10 ppm, and AA+Resv 20 ppm) are 96.88% (6.80%, n = 32), 76.67% (7.02%, n = 30), 
36.67% (7.02%, n = 30), and 83.33% (7.02%, n = 30), respectively. For “UA”, the mean malformation 
rates (standard error, sample size) for the four dose groups (AA only, AA+UA 1 ppm, AA+UA 10 ppm, 
and AA+UA 20 ppm) were 96.88% (4.75%, n = 32), 70.00% (4.91%, n = 30), 96.67% (4.91%, n = 30), 
and 100% (5.27%, n = 30), respectively. Figure 2E,F presents the mean malformation rates with  
95% confidence intervals of dosage groups for drugs “Resv” and “UA”, respectively. The findings show 
that the malformation rates for the “AA+Resv 10 ppm” group and “AA+UA 1 ppm” group were 
significantly lower than that for the “AA only” group. This suggests that both Resv with a dosage of  
10 ppm and UA with a dosage of 1 ppm have significant resistance effects against “AA” poisoning. 
 
Figure 2. Cont. 




Figure 2. Kidney phenotypes of zebrafish embryos after prevention (10 ppm Resv or UA). 
(A) No defect of mock group; (B) AA caused atrophic glomerulus and pronephric tube (pt) 
curved defect; (C and D) Prevention groups treated to restore a similar phenotype as the 
mock group. All kidney photos were taken from the dorsal view at the developmental stage 
of 48 hpf. Tg(wt1b:EGFP). pt, pronephric tubule; pd, pronephric duct; gl, glomerulus;  
(E,F) The Tukey-Kramer HSD (honestly significant difference) test: the mean malformation 
rates and their 95% confidence intervals for treatment groups. Two group means were 
considered significantly different if their intervals were disjointed and were not significantly 
different if their intervals overlapped. 
2.3. Resv and UA Treatment Attenuate AA-Induced Renal Failure 
For further confirmation of the protective effects of Resv/UA, we performed glomerular filtration rate 
(GFR) assays on zebrafish embryos. As shown in Figure 3A, GFR at 72 hpf in the AA-treated group was 
56.1% ±17.3% (n = 15) and increased to 80.2% ± 11.3% and 83.1% ± 8.1% in the Resv+AA and UA+AA 
groups (n = 15), respectively. This indicates that Resv and UA can partially restore kidney function. The 
average GFR (standard error, sample size) for the “mock”, “AA”, “AA+RESV”, and “AA+UA” groups 
were 79.15% (1.16%, n = 15), 44.44% (4.32%, n = 16), 63.50% (3.41%, n = 11), and 65.78% (2.55%,  
n = 10), respectively. The ANOVA test gives a very small p-value (<0.0001), indicating a highly 
significant difference in glomerular filtration rates between treatment groups. The Tukey-Kramer HSD 
test was then used to conduct pairwise comparisons of the average glomerular filtration rates of the 
different treatment groups. Figure 3B presents the average glomerular filtration rates of the treatment 
groups with 95% confidence intervals. The conclusions are as follows: (i) the average GFR of the “AA”, 
“AA+RESV”, and “AA+UA” groups were significantly lower than that of the “mock” group; (ii) the 
average GFR of the “AA+RESV” and “AA+UA” groups were significantly higher than that of the “AA” 
group; and (iii) the average GFR of the “AA+UA” group was higher than that of the “AA+RESV” group, 
although the difference was not significant. This suggests that Resv and UA treatment attenuate  
AA-induced renal failure. 




Figure 3. Glomerular filtration rates of Resv and UA prevent aristolochic acid nephropathy 
(AAN). (A) Zebrafish embryos were either exposed to water (no treatment) or water 
containing 5 ppm AA and 10 ppm Resv or UA exposure. Dextran tetramethylrhodamine was 
injected into the cardiac venous sinus of 72 hpf embryos derived from different groups 
(mock, prevention), and fluorescence intensities were recorded after 1 h post-injection (hpi) 
and 24 hpi (n = 15); (B) Tukey-Kramer HSD test: the mean glomerular filtration rates and 
their 95% confidence intervals for treatment groups (“Mock”, “AA “, “AA+Resv”, and 
“AA+UA”). Two group means were considered to be significantly different if their intervals 
were disjointed and were not significantly different if their intervals overlapped. 
2.4. Resv and UA Improve the Accumulation of Erythrocytes and Restoration of Blood Circulation 
Transgenic Tg(gata1:DsRed) zebrafish, in which the red blood cells can be identified by red 
fluorescence, are a useful tool for studying defects in blood circulation [27]. We have previously shown 
that AA-treated Tg(gata1:DsRed) embryos had abnormal blood circulation and red blood cell 
accumulation in the kidney [12]. In this study, the same strategy is applied to evaluate the  
nephro-preventive effects of Resv and UA. As shown in the supplementary movie, the distance between 
T0 (initial position of one red blood cell) and T1 (position of the red blood cell 1 s later) in AA-exposed 
embryos was shorter than that in the mock control group, indicating that blood circulation was blocked 
by AA exposure (Figure 4A,A' vs. 4B,B'). However, the distance between T0 and T1 in the Resv or UA 
prevention groups was longer than that of embryos in the AA-exposed group, suggesting that blood 
circulation was restored after treatment with either Resv or UA (Figure 4C,C' vs. 4D,D'). 




Figure 4. Effects of Resv or UA on blood circulation. Images were captured by live video 
(Supplementary movie S1) of Tg(gata1:DsRed) embryos without AA treatment (A,A') after 
3 ppm AA treatment (B,B') and Resv or UA prevention groups (C,C',D,D'). T0: Initial 
position of one red blood cell; T1: Position of the red blood cell 1 s later. 
Moreover, as evidenced by ο-dianisidine staining, AA-exposed embryos had abnormal accumulation 
of red blood cells in the tubular and glomerular regions (Figure 5A vs. 5B), but the blood accumulation 
was attenuated by treatment with either Resv or UA (Figure 5C,D). 
 
Figure 5. Resv or UA decrease AA-induced red blood cell accumulation. Embryos derived 
from the mock (no treatment: A), AA-treated group (B), and Resv (C) or UA prevention 
groups (D) were stained with ο-dianisidine. The black arrow indicates the position of the 
glomerulus. The red dots indicate the region of blood accumulation.  
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2.5. Treatment with Either Resv or UA Suppresses the Generation of ROS and the Inflammatory Response 
It has been reported that AA treatment leads to kidney inflammation [12,28]. In this regard, we further 
investigated whether AA-induced reactive oxygen species (ROS) are eliminated by Resv/UA treatment. 
As shown in Figure 6, AA-induced ROS fluorescence intensity was 1826 arbitrary units (a.u.).  
In contrast, AA-induced ROS fluorescence intensity was decreased to 609 and 690 a.u. (approximately 
a 63%–67% reduction) after treatment with either Resv or UA, respectively. These observations suggest 
that both Resv and UA were able to significantly reduce ROS production in zebrafish embryos. 
 
Figure 6. Concentration of reactive oxygen species (ROS) in zebrafish exposed to 3 ppm of 
AA and prevention groups (containing Resv or UA). Data (fluorescence intensity) are 
expressed as the mean ± standard error (n = 30). 
 
Figure 7. Quantitative real-time polymerase chain reaction (qPCR) analysis of the 
expression levels of marker genes ((A): TNFα; (B): mpo) between mock (no treatment),  
AA-treated, and Resv or UA prevention embryo groups. 
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The expression of pro-inflammatory genes was further examined by quantitative PCR (qPCR), and 
the results showed that the expression of TNFα and mpo in the AA-treated embryos increased by  
4.8- and 3.4-fold, respectively, in comparison with the mock control embryos (Figure 7). However, the 
expression of TNFα in the Resv+AA and UA+AA groups was decreased to 2.2- and 1.3-fold  
(Figure 7A); expression of mpo in the Resv+AA and UA+AA groups was decreased by 1.5- and  
1.0-fold, respectively (Figure 7B). These results suggest that the attenuation of AA-induced kidney 
malformation by both Resv and UA treatment may be mediated by suppression of pro-inflammatory 
gene expression. 
3. Experimental Section 
3.1. Fish Maintenance and Embryo Collection 
Zebrafish (wild type, WT; AB strain), Tg(wt1b:EGFP) and Tg(gata1:DsRed) [25,26,29] were 
maintained in 16–20 gallon tanks at 28.5 °C under a 14/10 h light-dark cycle. Their embryos were 
collected according to standard criteria (hours post-fertilization, hpf, or days post-fertilization, dpf [30]. 
All animal experiments in this study were performed in accordance with the guidelines issued by the 
animal ethics committee of Tamkang University. 
3.2. Chemical Exposure and Survival Rate Analysis 
We employed a previously described aristolochic acid (AA) exposure protocol [12] to evaluate the 
nephroprotective effects of resveratrol (Resv; trans-3,4,5-trihydroxystilbene) and ursolic acids  
(UA; C30H48O3). In the present study, four exposure protocols were used: (I) Mock: water only; (II) AA: 
embryos were exposed to AA from 24 to 31 hpf; (III) Resv+AA: embryos were soaked in Resv  
(12–24 hpf) prior to AA exposure; and (IV) UA+AA: embryos were soaked in UA (12–24 hpf) prior to 
AA exposure. For dose titration and survival rate analysis, Tg(wt1b:EGFP) embryos (by 12 hpf) were 
collected (30 embryos per group) and were exposed according to the above-mentioned protocols, 
differing in the addition of either Resv or UA at different concentrations (0, 1, 10 and 20 ppm). All 
embryos were cultivated in 24-well cell culture plates, and survival rates were counted at the check point. 
3.3. Detection of ROS and Data Analysis 
To detect the accumulation of ROS, embryos were incubated with 500 ng/mL 
dihydrodichlorofluorescein diacetate (H2DCFDA). Intracellular H2DCFDA was de-esterified to 
dichlorodihydrofluorescein, which was oxidized by ROS to produce the fluorescent compound 
dichlorofluorescein (DCF). After a 60-min incubation at 28 °C, the fluorescence intensity (FI) of the 
embryos was measured at an excitation/emission = 485/530 nm. 
3.4. Zebrafish Renal Function Assay 
The procedure used for the detection of acute renal failure was described previously [31]. In brief, 
zebrafish embryos were anesthetized in 40 μg/mL tricaine (ethyl-m-aminobenzoate methanesulfonate 
salt, Sigma, St. Louis, MO, USA) and positioned in an injection holder. Tetramethylrhodamine-labeled 
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10-kDa dextran (Molecular Probes, Eugene, OR, USA) was injected into the cardiac venous sinus at  
72 h post-fertilization, and individual fluorescence intensity at baseline, 1 and 24 h was measured in 
each fish. The fluorescence intensity ratios were defined using image J analysis software (1.47q, NIH, 
Bethesda, MD, USA, 2013). 
3.5. Red Blood Cell Staining 
The procedure for detecting erythropoiesis was described previously [32] and was used in the present 
study with minor modification. Embryos at 48 hpf were bathed in a stain buffer with combinations of  
0.6 mg/mL ο-dianisidine in 40% ethanol, 10 mM sodium acetate, pH 5.2, and 0.65% hydrogen peroxide 
and incubated in the dark at room temperature for 15 min. Embryos were washed with PBS, fixed in 4% 
paraformaldehyde, and observed under a dissection microscope (Leica, Wetzlar, Germany). 
3.6. Histology and Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR) 
The experimental procedures for cryosectioning and qRT-PCR have been previously described [33–35], 
except that primer sets were synthesized for detecting the expression levels of TNFα and mpo.  
The housekeeping gene β-actin was used as an internal control for normalization in quantification. 
3.7. Images 
All of the embryos were observed under a microscope (DM 2500, Leica, Wetzlar, Germany) equipped 
with Nomarski distinguishing interference contrast optics and a fluorescent module including GFP, 
DsRed and DAPI filter cubes (Kramer Scientific, Amesbury, MA, USA). Pictures of the embryos were 
captured at particular stages with a CoolSNAP CCD (Photometrics, Tucson, AZ, USA). A 15-s movie 
of the embryos at 48 hpf was recorded (SONY, Tokyo, Japan). 
3.8. Statistical Analysis 
All analyses in this study were carried out using Matlab software (version 7.7 R2008b, MathWorks, 
Natick, MA, USA, 2008). ANOVA (analysis of variance) was applied to examine the effect of dose on 
the mean malformation rate. The p-value reported by ANOVA indicated that samples in all dosage 
groups are drawn from the same population. The Tukey-Kramer HSD (honestly significant difference) 
test was further used to compare the population mean malformation rate for each dosage group.  
A significance level of 0.05 was used in all statistical analyses, and a family-wise error rate of 0.05 was 
used in the Tukey-Kramer HSD test. 
4. Conclusions 
In mice and humans, pro-inflammatory responses of renal endothelial cells and activation of 
inflammatory leukocytes reduce renal blood flow by vascular congestion and consequently cause kidney 
malformations [36,37]. Similarly, aristolochic acid (AA)-induced nephropathy is mediated by 
inflammation in both mice and zebrafish [12,28]. In the present study, we tested whether AA-induced 
nephropathy can be attenuated by treating the developing zebrafish embryos with natural  
anti-inflammatory agents such as resveratrol (Resv) and ursolic acid (UA). Our studies revealed that AA 
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can induce an inflammatory response associated with the progression of circulation and kidney defects 
in zebrafish embryos and that such an inflammatory response can be attenuated by pre-treatment with 
either Resv or UA. In conclusion, we believe that zebrafish represent an efficient model for screening 
AA-protective natural compounds. 
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